Media ReleasesImmutep

View All Immutep News


Immutep secures commitments for A$60 million in a Placement


Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or Company), is pleased to announce that it has received commitments for a A$60 million via a two-tranche placement of new ordinary shares in Immutep (New Shares) to professional, institutional and sophisticated investors (Placement).

Immutep CEO, Marc Voigt said: “Never has there been a more exciting time to be the leading LAG-3 biotech, following the recent industry validation of this promising new immune checkpoint. Efti has continued to report compelling results from multiple clinical trials over the last year, including from key patient subgroups in our AIPAC study. Efti will be tested in different late-stage randomised settings which is a key step towards potential commercialisation.

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.